Download presentation
Presentation is loading. Please wait.
Published byElijah Bryant Modified over 6 years ago
1
Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC
2
Activity Goals
3
Patient Case Study
4
Patient History
5
CheckMate 017: Nivolumab vs Docetaxel in Refractory, Squamous, Advanced NSCLCa
6
CheckMate 017: Results in Squamous NSCLC
7
CheckMate 057: Nivolumab vs Docetaxel in Refractory, Advanced Non-squamous NSCLC
8
CheckMate 057: Results
9
Checkpoint Inhibitors Being Evaluated for the First-Line Treatment of NSCLC
10
First-line Treatment of NSCLC
11
PDL1: Challenges in Biomarker Development
12
CheckMate 057: OS Based on PD-L1 Expression
13
CheckMate 057: Response Rates
14
Current Status of PD-1 Inhibitors in Clinical Practice
15
Pembrolizumab in Patients With Brain Metastases: Phase 2 Study
16
Efficacy of Immunotherapy
17
Patient History (Follow-up)
18
Outstanding Issues
19
Immune-Mediated Adverse Events With PD-1 Inhibitors
20
Abbreviations
21
References
22
References (cont)
23
References (cont)
24
References (cont)
25
References (cont)
26
References (cont)
27
References (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.